-
摘要: 过去十年，肾细胞癌的治疗格局已经发生了转变，包括在辅助治疗中加入免疫检查点抑制剂的联合疗法。随着近年来临床药物试验的开展，围绕手术、非手术、一线、二线治疗方案仍存在许多争议，包括转移性疾病的治疗选择和风险评估模型的效用。为了在疾病的所有阶段选择最合适的治疗方式，临床工作者和科学家需要更加拓宽视野，例如将目光从IMDC风险预后评估模型转移到个性化生物标志物靶点治疗。文本拟对目前肾细胞癌治疗的新进展展开论述，旨在为局限性及晚期肾癌患者的诊疗工作提供借鉴意义。Abstract: Over the past decade, the treatment landscape for renal cell carcinoma has shifted, including combination therapies that add immune checkpoint inhibitors to adjuvant therapy. With the development of clinical drug trials in recent years, there are still controversies surrounding surgical, non-surgical, first-line and second-line treatment options, including treatment options for metastatic diseases and the effectiveness of risk assessment models. In order to select the most appropriate treatment at all stages of the disease, clinicians and scientists need to broaden their horizons, such as shifting their focus from IMDC risk and prognosis assessment models to personalized biomarker target therapy. This paper intends to discuss the current new progress in the treatment of renal cell carcinoma, aiming to provide reference for the diagnosis and treatment of patients with localized and advanced renal cancer.
-
Key words:
- renal cell carcinoma /
- surgery /
- targeted therapy /
- immune
-
-
[1] van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma[J]. Eur Urol, 2011, 59(4): 543-552. doi: 10.1016/j.eururo.2010.12.013
[2] Miller DC, Schonlau M, Litwin MS, et al. Renal and cardiovascular morbidity after partial or radical nephrectomy[J]. Cancer, 2008, 112(3): 511-520. doi: 10.1002/cncr.23218
[3] Delahunt B, Eble JN, Samaratunga H, et al. Staging of renal cell carcinoma: current progress and potential advances[J]. Pathology, 2021, 53(1): 120-128. doi: 10.1016/j.pathol.2020.08.007
[4] Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis[J]. BJU Int, 2018, 121(5): 684-698. doi: 10.1111/bju.14127
[5] Breen DJ, King AJ, Patel N, et al. Image-guided cryoablation for sporadic renal cell carcinoma: three-and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma[J]. Radiology, 2018, 289(2): 554-561. doi: 10.1148/radiol.2018180249
[6] Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials[J]. Cancer, 2003, 97(7): 1663-1671. doi: 10.1002/cncr.11234
[7] Correa RJM, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis[J]. Eur Urol Focus, 2019, 5(6): 958-969. doi: 10.1016/j.euf.2019.06.002
[8] Zhou WH, Herwald SE, McCarthy C, et al. Radiofrequency ablation, cryoablation, and microwave ablation for T1a renal cell carcinoma: a comparative evaluation of therapeutic and renal function outcomes[J]. J Vasc Interv Radiol, 2019, 30(7): 1035-1042. doi: 10.1016/j.jvir.2018.12.013
[9] Stewart GD, Welsh SJ, Ursprung S, et al. A Phase Ⅱ study of neoadjuvant axitinib for reducing the extent of venous tumourThrombusin clear cell renal cell cancer with venous invasion(NAXIVA)[J]. Br J Cancer, 2022, 127(6): 1051-1060. doi: 10.1038/s41416-022-01883-7
[10] Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma(KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(9): 1133-1144. doi: 10.1016/S1470-2045(22)00487-9
[11] Motzer RJ, Russo P, Gruenwald V, et al. LBA4 adjuvant nivolumab plus ipilimumab(NIVO+IPI)vs placebo(PBO)for localized renal cell carcinoma(RCC)at high risk of relapse after nephrectomy: results from the randomized, phase Ⅲ CheckMate 914 trial[J]. Ann Oncol, 2022, 33: S1430.
[12] Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection(IMmotion010): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2022, 400(10358): 1103-1116. doi: 10.1016/S0140-6736(22)01658-0
[13] Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results[J]. Eur Urol, 2018, 73(1): 62-68. doi: 10.1016/j.eururo.2017.09.008
[14] Haas NB, Manola J, Dutcher JP, et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial[J]. JAMA Oncol, 2017, 3(9): 1249-1252. doi: 10.1001/jamaoncol.2017.0076
[15] Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase Ⅲ intergroup trial[J]. J Clin Oncol, 2020, 38(34): 4064-4075. doi: 10.1200/JCO.20.01800
[16] Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase Ⅲ, randomized ATLAS trial[J]. Ann Oncol, 2018, 29(12): 2371-2378. doi: 10.1093/annonc/mdy454
[17] Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol, 2004, 171(3): 1071-1076. doi: 10.1097/01.ju.0000110610.61545.ae
[18] Larcher A, Fallara G, Rosiello G, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines[J]. Eur Urol, 2020, 78(3): 321-326. doi: 10.1016/j.eururo.2020.05.014
[19] Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: results from 30-month follow-up of KEYNOTE-564[J]. J Clin Oncol, 2022, 40(6_suppl): 290. doi: 10.1200/JCO.2022.40.6_suppl.290
[20] Siva S, Bressel M, Wood ST, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial[J]. Eur Urol, 2022, 81(4): 364-372. doi: 10.1016/j.eururo.2021.12.006
[21] Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma(KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573. doi: 10.1016/S1470-2045(20)30436-8
[22] Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. doi: 10.1056/NEJMoa2035716
[23] Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841. doi: 10.1056/NEJMoa2026982
[24] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. doi: 10.1056/NEJMoa1712126
[25] Ko JJ, Xie WL, Kroeger N, et al. The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study[J]. Lancet Oncol, 2015, 16(3): 293-300. doi: 10.1016/S1470-2045(14)71222-7
[26] Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon Alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2023, 41(11): 1965-1971. doi: 10.1200/JCO.22.02623
[27] Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis[J]. Ann Oncol, 2015, 26(10): 2107-2113. doi: 10.1093/annonc/mdv315
[28] Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk(alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update[J]. Eur J Cancer, 2018, 94: 115-125. doi: 10.1016/j.ejca.2018.02.012
[29] Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial[J]. Lancet Oncol, 2016, 17(9): 1317-1324. doi: 10.1016/S1470-2045(16)30196-6
[30] Tannir NM, Escudier B, McDermott DF, et al. Nivolumab plus ipilimumab(NIVO+IPI)vs sunitinib(SUN)for first-line treatment of advanced renal cell carcinoma(aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial[J]. J Clin Oncol, 2024, 42(4_suppl): 363. doi: 10.1200/JCO.2024.42.4_suppl.363
[31] Ornstein MC, Pal SK, Wood LS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2019, 20(10): 1386-1394. doi: 10.1016/S1470-2045(19)30513-3
[32] Albiges L, Schmidinger M, Taguieva-Pioger N, et al. CaboPoint: a phase Ⅱ study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma[J]. Future Oncol, 2022, 18(8): 915-926. doi: 10.2217/fon-2021-1006
[33] Powles TB, Oudard S, Grünwald V, et al. 718P A phase Ⅱ study of patients with advanced or metastatic renal cell carcinoma(mRCC)receiving pazopanib after previous checkpoint inhibitor treatment[J]. Ann Oncol, 2020, 31: S564.
[34] Albiges L, Rini BI, Peltola K, et al. LBA88 belzutifan versus everolimus in participants(pts)with previously treated advanced clear cell renal cell carcinoma(ccRCC): randomized open-label phase Ⅲ LITESPARK-005 study[J]. Ann Oncol, 2023, 34: S1329-S1330. doi: 10.1016/j.annonc.2023.10.090
[35] Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von hippel-lindau disease[J]. N Engl J Med, 2021, 385(22): 2036-2046. doi: 10.1056/NEJMoa2103425
[36] Neth BJ, Webb MJ, White J, et al. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience[J]. J Neurooncol, 2023, 164(1): 239-247. doi: 10.1007/s11060-023-04395-3
[37] Dhawan A, Peereboom DM, Stevens GH. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma[J]. CNS Oncol, 2022, 11(3): CNS91. doi: 10.2217/cns-2022-0008
[38] Srinivasan R, Iliopoulos O, Rathmell WK, et al. LBA69 belzutifan, a HIF-2α inhibitor, for von hippel-lindau(VHL)disease-associated neoplasms: 36 months of follow-up of the phase Ⅱ LITESPARK-004 study[J]. Ann Oncol, 2022, 33: S1433-S1434.
[39] Tannir NM, Agarwal N, Porta C, et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial[J]. JAMA Oncol, 2022, 8(10): 1411-1418. doi: 10.1001/jamaoncol.2022.3511
[40] Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial[J]. Cancer, 2020, 126(18): 4156-4167. doi: 10.1002/cncr.33033
[41] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813. doi: 10.1056/NEJMoa1510665
-
计量
- 文章访问数: 1013
- PDF下载数: 147
- 施引文献: 0
下载: